Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VRAX
stocks logo

VRAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Valuation Metrics

The current forward P/E ratio for Virax Biolabs Group Ltd (VRAX.O) is -0.64, compared to its 5-year average forward P/E of -3.23. For a more detailed relative valuation and DCF analysis to assess Virax Biolabs Group Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.23
Current PE
-0.64
Overvalued PE
1.92
Undervalued PE
-8.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.26
Undervalued EV/EBITDA
-7.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
46.63
Current PS
0.00
Overvalued PS
164.06
Undervalued PS
-70.79
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VRAX News & Events

Events Timeline

(ET)
2025-11-03
08:32:19
Virax finishes enrolling patients for its clinical trial assessing ViraxImmun.
select
2025-08-26 (ET)
2025-08-26
07:33:03
Virax Biolabs Collaborates with Emory University for ViraxImmune Clinical Trials
select
2025-07-18 (ET)
2025-07-18
22:22:29
Virax Biolabs receives noncompliance notice from Nasdaq
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04NASDAQ.COM
PinnedVirax Biolabs Announces $5 Million Private Placement Deal

  • Share Purchase Agreement: Virax Biolabs Group Limited has entered into an agreement to sell 12.5 million shares at $0.40 each, aiming for gross proceeds of $5 million.

  • Use of Proceeds: The company plans to utilize the net proceeds for working capital and general corporate purposes, with the private placement expected to close around December 4, 2025.

  • Regulatory Compliance: Virax Biolabs will complete necessary SEC paperwork within 45 days to enable investors to legally resell their shares.

  • Stock Performance: Following a significant increase of 75.11% in the previous trading session, the stock is down 16.16% in pre-market trading.

[object Object]
Preview
8.5
12-04Benzinga
PinnedVirax Biolabs (VRAX) Shares Decline in After-Hours Trading After 75% Surge

  • Stock Performance: Virax Biolabs Group Ltd (NASDAQ: VRAX) shares fell 12.79% to $0.60 in after-hours trading, despite closing at $0.69, a 75.11% increase for the day. The stock has declined 68.87% year-to-date.

  • Private Placement Announcement: The company announced a private placement of 12.5 million ordinary shares at $0.40 each, expected to raise $5 million before fees, with H.C. Wainwright & Co. as the exclusive placement agent.

  • Warrant Modifications: The offering includes preferred investment options priced at $0.40 per share, with modifications to existing Series A and B options to match the new price and extend their expiration to five years.

  • Use of Proceeds: Virax plans to use the net proceeds from the private placement for working capital and general corporate purposes, with the transaction expected to close soon, subject to customary conditions.

[object Object]
Preview
8.5
12-04Newsfilter
PinnedVirax Biolabs Secures $5 Million by Issuing 12.5 Million Shares at $0.40 Each
  • Financing Scale: Virax Biolabs is raising $5 million through a private placement of 12.5 million ordinary shares at $0.40 each, which will enhance the company's financial flexibility for working capital and general corporate purposes.
  • Investor Agreement: The company has committed to filing an initial registration statement with the SEC within 45 days, covering the ordinary shares and preferred investment options, ensuring future liquidity and access to capital markets.
  • Preferred Investment Options: The preferred investment options have an exercise price of $0.40 per share and can be exercised immediately for five years, providing an additional capital source to support R&D and market expansion.
  • Market Reaction: Although this financing is not a public offering, its successful completion is expected to boost market confidence in Virax's biotechnology initiatives, further advancing its immunology research and diagnostic technologies.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Virax Biolabs Group Ltd (VRAX) stock price today?

The current price of VRAX is 0.644 USD — it has decreased -6.4 % in the last trading day.

arrow icon

What is Virax Biolabs Group Ltd (VRAX)'s business?

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

arrow icon

What is the price predicton of VRAX Stock?

Wall Street analysts forecast VRAX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Virax Biolabs Group Ltd (VRAX)'s revenue for the last quarter?

Virax Biolabs Group Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Virax Biolabs Group Ltd (VRAX)'s earnings per share (EPS) for the last quarter?

Virax Biolabs Group Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Virax Biolabs Group Ltd (VRAX)'s fundamentals?

The market is revising No Change the revenue expectations for Virax Biolabs Group Limited (VRAX) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 13.98%.
arrow icon

How many employees does Virax Biolabs Group Ltd (VRAX). have?

Virax Biolabs Group Ltd (VRAX) has 19 emplpoyees as of December 05 2025.

arrow icon

What is Virax Biolabs Group Ltd (VRAX) market cap?

Today VRAX has the market capitalization of 2.80M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free